Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion.

@article{Jahns2008PeripartumCN,
  title={Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion.},
  author={Boriana G Jahns and W. Stein and Denise Hilfiker-Kleiner and Burkert Pieske and Guenter Emons},
  journal={American journal of obstetrics and gynecology},
  year={2008},
  volume={199 4},
  pages={e5-6}
}
Peripartum cardiomyopathy (PPCM) is a rare disease of unclear etiology with a frequent poor outcome, despite optimal medical therapy. Recent experimental data implicate a causal role of prolactin. We report a patient with PPCM who responded well to treatment with Bromocriptine in addition to standard therapy of heart failure.